A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Clinical trial NCT04849273 · TERMINATED

Trial details

NCT number: NCT04849273
Sponsor: Turning Point Therapeutics, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer Non-Small Cell Lung Cancer NSCLC Advanced Solid Tumor Metastatic Solid Tumor ALK Gene Mutation

Start date: 2021-07-28
Primary completion: 2023-04-18
Enrollment: 11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.